In a lung orthotopic tumor model, a hybrid siRNA (anti-Survivin and anti-MDR1 (siSM))-loaded PGS delivery system decreased the tumor growth, while concurrent administration of PGS/siSM and cisplatin synergistically enhanced this effect and significantly improved life span. This evidence concerns the gene ABCB1 and neoplasm.